Lake Resources N.L.

LKE

Lake Resources NL, is a lithium exploration company, which is focused on exploring lithium basins and pegmatites in Argentina. The company is headquartered in Sydney, New South Wales. The company went IPO on 2001-08-29. is an Australia-based company, which is engaged in exploring and developing lithium brine projects in Argentina. The Company’s projects include Kachi Project, Cauchari Project, Olaroz Project, Paso Project and Catamarca Pegmatite project. The Kachi Project is located in Argentina’s Catamarca Province at the southern end of the Lithium Triangle and consists of an area of approximately 705 square kilometers (km). The Cauchari Project consists of an area of approximately 480 square km in Argentina’s Jujuy Province. The Olaroz Project is located in Argentina’s Jujuy Province, approximately 15 km north-east of Orocobre’s lithium production facility. The Paso Project is located in Argentina’s Jujuy Province, approximately 30 km west of Orocbre’s lithium production facility. The Catamarca Pegmatite project is located in Argentina’s Catamarca Province and covers an area of approximately 720 square km.

ETHI

ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.

Core Lithium Ltd

CXO

Core Lithium Ltd. is an Australian based mineral exploration company, which engages in the acquisition, exploration, evaluation, and development of copper, gold, uranium, and iron ore properties. The company is headquartered in Adelaide, South Australia. The company went IPO on 2011-02-11. The firm owns and operates Finniss Lithium project, which is located south of Darwin Port in the Northern Territory. The project lies within a prospective area for lithium in the NT, the Bynoe Pegmatite Field, and covers approximately 500 square kilometers (km2) of granted tenements. The project is approximately 88 kilometers (km) by sealed road from Darwin Port, Northern Territory. Its other projects include Shoobridge Lithium, Anningie and Barrow Creek Lithium, Sa Zinc, Jervois Domain, Blueys and Inkheart Lead/Silver, Bynoe Gold, Fitton Uranium, and Napperby Uranium. Shoobridge Lithium project is located approximately 80 km south-southeast of Finniss near Darwin in the Northern Territory. Sa Zinc project covers a total area of approximately 500 km2 in northern South Australia. Jervois Domain project covers three exploration licenses in the central Northern Territory.

ACDC

ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).

Imugene Limited

IMU

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The firm is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies, such as CAR T’s for solid tumors. Its HER-Vaxx is a B-cell immuno-therapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. PD1-Vaxx is a B-cell immuno-therapy, which aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer. Its clinical trial candidates include VAXINIA, CHECKvacc, B-Vaxx and others. Its platform technologies seek to harness the body’s immune system against tumors.